Compare CCHH & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | IMNN |
|---|---|---|
| Founded | 2015 | 1982 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.5M |
| IPO Year | N/A | 2000 |
| Metric | CCHH | IMNN |
|---|---|---|
| Price | $0.52 | $2.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 103.6K | 37.7K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.37 |
| 52 Week High | $15.39 | $9.32 |
| Indicator | CCHH | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 39.09 |
| Support Level | $0.49 | $2.52 |
| Resistance Level | $0.68 | $3.24 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 8.24 | 11.63 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.